Bacterial Lipopolysaccharide Augmented Malignant Transformation and Promoted the Stemness in Prostate Cancer Epithelial Cells

References

• Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133(4):704–715. doi:10.1016/j.cell.2008.03.027
   PubMed Web of Science ®Google Scholar
• Bessede E, Staedel C, Acuna Amador LA, et al. Helicobacter pylori generates cells with cancer stem cell properties via epithelial-mesenchymal transition-like changes. Oncogene. 2014;33(32):4123–4131. doi:10.1038/onc.2013.380
   PubMed Web of Science ®Google Scholar
• Shuang ZY, Wu WC, Xu J, et al. Transforming growth factor-beta1-induced epithelial-mesenchymal transition generates ALDH-positive cells with stem cell properties in cholangiocarcinoma. Cancer Lett. 2014;354(2):320–328. doi:10.1016/j.canlet.2014.08.030
   PubMed Web of Science ®Google Scholar
• Weiswald LB, Bellet D, Dangles-Marie V. Spherical cancer models in tumor biology. Neoplasia. 2015;17(1):1–15. doi:10.1016/j.neo.2014.12.004
   PubMed Web of Science ®Google Scholar
• Tsunekuni K, Konno M, Haraguchi N, et al. CD44/CD133-positive colorectal cancer stem cells are sensitive to trifluridine exposure. Sci Rep. 2019;9(1):14861. doi:10.1038/s41598-019-50968-6
   PubMedGoogle Scholar
• Weissenrieder JS, Reed JL, Green MV, et al. The dopamine D2 receptor contributes to the spheroid formation behavior of U87 glioblastoma cells. Pharmacology. 2020;105(1–2):19–27. doi:10.1159/000502562
   PubMed Web of Science ®Google Scholar
• Lee CH, Yu CC, Wang BY, Chang WW. Tumorsphere as an effective in vitro platform for screening anti-cancer stem cell drugs. Oncotarget. 2016;7(2):1215–1226. doi:10.18632/oncotarget.6261
   PubMedGoogle Scholar
• Ellner HJ, Miller GC. Prostatic abscess simulating carcinoma. Northwest Med. 1964;63:174–175.
   PubMedGoogle Scholar
• Jameson RM. Prostatic abscess and carcinoma of the prostate. Br J Urol. 1968;40(3):288–292. doi:10.1111/j.1464-410X.1968.tb09889.x
   PubMedGoogle Scholar
• Ohadian Moghadam S, Momeni SA. Human microbiome and prostate cancer development: current insights into the prevention and treatment. Front Med. 2021;15(1):11–32.
   PubMed Web of Science ®Google Scholar
• Bruggemann H, Al-Zeer MA. Bacterial signatures and their inflammatory potentials associated with prostate cancer. APMIS. 2020;128(2):80–91. doi:10.1111/apm.13021
   PubMed Web of Science ®Google Scholar
• Cario E, Rosenberg IM, Brandwein SL, Beck PL, Reinecker HC, Podolsky DK. Lipopolysaccharide activates distinct signaling pathways in intestinal epithelial cell lines expressing Toll-like receptors. J Immunol. 2000;164(2):966–972. doi:10.4049/jimmunol.164.2.966
   PubMed Web of Science ®Google Scholar
• Li H, Li Y, Liu D, Liu J. LPS promotes epithelial-mesenchymal transition and activation of TLR4/JNK signaling. Tumour Biol. 2014;35(10):10429–10435. doi:10.1007/s13277-014-2347-5
   PubMed Web of Science ®Google Scholar
• Li XY, Yang X, Zhao QD, et al. Lipopolysaccharide promotes tumorigenicity of hepatic progenitor cells by promoting proliferation and blocking normal differentiation. Cancer Lett. 2017;386:35–46. doi:10.1016/j.canlet.2016.10.044
   PubMed Web of Science ®Google Scholar
• Tian QX, Zhang ZH, Ye QL, et al. Melatonin inhibits migration and invasion in LPS-stimulated and -unstimulated prostate cancer cells through blocking multiple EMT-relative pathways. J Inflamm Res. 2021;14:2253–2265. doi:10.2147/JIR.S305450
   PubMed Web of Science ®Google Scholar
• Xing WY, Zhang ZH, Xu S, et al. Calcitriol inhibits lipopolysaccharide-induced proliferation, migration and invasion of prostate cancer cells through suppressing STAT3 signal activation. Int Immunopharmacol. 2020;82:106346. doi:10.1016/j.intimp.2020.106346
   PubMed Web of Science ®Google Scholar
• Nam HW, Bae J, Kim YW, et al. Anti-cancer effects of RAW 264.7 cells on prostate cancer PC-3 cells. Ann Clin Lab Sci. 2020;50(6):739–746.
   PubMed Web of Science ®Google Scholar
• Lee CF, Dang A, Hernandez E, et al. Activation of sphingosine kinase by lipopolysaccharide promotes prostate cancer cell invasion and metastasis via SphK1/S1PR4/matriptase. Oncogene. 2019;38(28):5580–5598. doi:10.1038/s41388-019-0833-3
   PubMed Web of Science ®Google Scholar
• Li J, Chong T, Wang Z, et al. A novel anticancer effect of resveratrol: reversal of epithelial mesenchymal transition in prostate cancer cells. Mol Med Rep. 2014;10(4):1717–1724. doi:10.3892/mmr.2014.2417
   PubMed Web of Science ®Google Scholar
• Huo SF, Shang WL, Yu M, et al. STEAP1 facilitates metastasis and epithelial-mesenchymal transition of lung adenocarcinoma via the JAK2/STAT3 signaling pathway. Biosci Rep. 2020;40(6). doi:10.1042/BSR20193169.
   Google Scholar
• Huang R, Wang S, Wang N, et al. CCL5 derived from tumor-associated macrophages promotes prostate cancer stem cells and metastasis via activating beta-catenin/STAT3 signaling. Cell Death Dis. 2020;11(4):234. doi:10.1038/s41419-020-2435-y
   PubMed Web of Science ®Google Scholar
• Wang X, Xu J, Wang H, et al. Trichostatin A, a histone deacetylase inhibitor, reverses epithelial-mesenchymal transition in colorectal cancer SW480 and prostate cancer PC3 cells. Biochem Biophys Res Commun. 2015;456(1):320–326. doi:10.1016/j.bbrc.2014.11.079
   PubMed Web of Science ®Google Scholar
• Xu F, Liu Z, Liu R, et al. Epigenetic induction of tumor stemness via the lipopolysaccharide-TET3-HOXB2 signaling axis in esophageal squamous cell carcinoma. Cell Commun Signal. 2020;18(1):17. doi:10.1186/s12964-020-0510-8
   PubMed Web of Science ®Google Scholar
• Huang CF, Chen L, Li YC, et al. NLRP3 inflammasome activation promotes inflammation-induced carcinogenesis in head and neck squamous cell carcinoma. J Exp Clin Cancer Res. 2017;36(1):116. doi:10.1186/s13046-017-0589-y
   PubMedGoogle Scholar
• Fan F, Wang R, Boulbes DR, et al. Macrophage conditioned medium promotes colorectal cancer stem cell phenotype via the hedgehog signaling pathway. PLoS One. 2018;13(1):e0190070. doi:10.1371/journal.pone.0190070
   PubMed Web of Science ®Google Scholar
• Ou T, Lilly M, Jiang W. The pathologic role of Toll-Like receptor 4 in prostate cancer. Front Immunol. 2018;9:1188. doi:10.3389/fimmu.2018.01188
   PubMed Web of Science ®Google Scholar
• Kundu SD, Lee C, Billips BK, et al. The toll-like receptor pathway: a novel mechanism of infection-induced carcinogenesis of prostate epithelial cells. Prostate. 2008;68(2):223–229. doi:10.1002/pros.20710
   PubMed Web of Science ®Google Scholar
• Omabe M, Omabe K, Okwuegbu M, Grace O, Okoro DU. Exposure of prostate to lipopolysaccharide and hypoxia potentiates neoplastic behavior and risk for prostate carcinogenesis in vivo. Int Sch Res Notices. 2014;2014:420429.
   PubMedGoogle Scholar
• Bernardo MM, Meng Y, Lockett J, et al. Maspin reprograms the gene expression profile of prostate carcinoma cells for differentiation. Genes Cancer. 2011;2(11):1009–1022. doi:10.1177/1947601912440170
   PubMedGoogle Scholar
• Yoshida M, Kijima M, Akita M, Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem. 1990;265(28):17174–17179. doi:10.1016/S0021-9258(17)44885-X
   PubMed Web of Science ®Google Scholar
• Li X, Chen BD. Histone deacetylase inhibitor M344 inhibits cell proliferation and induces apoptosis in human THP-1 leukemia cells. Am J Biomed Sci. 2009;1(4):352–363. doi:10.5099/aj090400352
   PubMedGoogle Scholar
• Liao L, Zhang XD, Li J, et al. Pioglitazone attenuates lipopolysaccharide-induced depression-like behaviors, modulates NF-kappaB/IL-6/STAT3, CREB/BDNF pathways and central serotonergic neurotransmission in mice. Int Immunopharmacol. 2017;49:178–186. doi:10.1016/j.intimp.2017.05.036
   PubMed Web of Science ®Google Scholar
• Weiss U. Inflammation. Nature. 2008;454(7203):427. doi:10.1038/454427a
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–444. doi:10.1038/nature07205
   PubMed Web of Science ®Google Scholar
• iegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.
   PubMed Web of Science ®Google Scholar
• De Nunzio C, Kramer G, Marberger M, et al. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur Urol. 2011;60(1):106–117. doi:10.1016/j.eururo.2011.03.055
   PubMed Web of Science ®Google Scholar
• Sciarra A, Gentilucci A, Salciccia S, et al. Prognostic value of inflammation in prostate cancer progression and response to therapeutic: a critical review. J Inflamm. 2016;13:35. doi:10.1186/s12950-016-0143-2
   Google Scholar
• Azad N, Zahnow CA, Rudin CM, Baylin SB. The future of epigenetic therapy in solid tumours–lessons from the past. Nat Rev Clin Oncol. 2013;10(5):256–266. doi:10.1038/nrclinonc.2013.42
   PubMed Web of Science ®Google Scholar
• Zhang T, Pilko A, Wollman R. Loci specific epigenetic drug sensitivity. Nucleic Acids Res. 2020;48:4797–4810.
   PubMed Web of Science ®Google Scholar
• De Souza C, Chatterji BP. HDAC inhibitors as novel anti-cancer therapeutics. Recent Pat Anticancer Drug Discov. 2015;10(2):145–162. doi:10.2174/1574892810666150317144511
   PubMed Web of Science ®Google Scholar
• Zhang H, Zhao X, Liu H, Jin H, Trichostatin JY. A inhibits proliferation of PC3 prostate cancer cells by disrupting the EGFR pathway. Oncol Lett. 2019;18(1):687–693.
   PubMed Web of Science ®Google Scholar
• Liu X, Zhang Y, Gao H, et al. Induction of an MLKL mediated non-canonical necroptosis through reactive oxygen species by tanshinol A in lung cancer cells. Biochem Pharmacol. 2020;171:113684. doi:10.1016/j.bcp.2019.113684
   PubMed Web of Science ®Google Scholar
• Zhou R, Yang Y, Park SY, et al. p300/CBP-associated factor promotes autophagic degradation of delta-catenin through acetylation and decreases prostate cancer tumorigenicity. Sci Rep. 2019;9(1):3351. doi:10.1038/s41598-019-40238-w
   PubMedGoogle Scholar
• Dzinic SH, Bernardo MM, Li X, et al. An essential role of maspin in embryogenesis and tumor suppression. Cancer Res. 2017;77(4):886–896. doi:10.1158/0008-5472.CAN-16-2219
   PubMed Web of Science ®Google Scholar
• Tang S, Lian X, Jiang J, et al. Tumor suppressive maspin-sensitized prostate cancer to drug treatment through negative regulating androgen receptor expression. Front Cell Dev Biol. 2020;8:573820. doi:10.3389/fcell.2020.573820
   PubMed Web of Science ®Google Scholar
• Taghiyev AF, Guseva NV, Sturm MT, Rokhlin OW, Cohen MB. Trichostatin A (TSA) sensitizes the human prostatic cancer cell line DU145 to death receptor ligands treatment. Cancer Biol Ther. 2005;4(4):382–390. doi:10.4161/cbt.4.4.1615
   PubMed Web of Science ®Google Scholar
• Kong D, Ahmad A, Bao B, Li Y, Banerjee S, Sarkar FH. Histone deacetylase inhibitors induce epithelial-to-mesenchymal transition in prostate cancer cells. PLoS One. 2012;7(9):e45045. doi:10.1371/journal.pone.0045045
   PubMed Web of Science ®Google Scholar
• Han RF, Li K, Yang ZS, Chen ZG, Yang WC. Trichostatin A induces mesenchymal-like morphological change and gene expression but inhibits migration and colony formation in human cancer cells. Mol Med Rep. 2014;10(6):3211–3216. doi:10.3892/mmr.2014.2594
   PubMed Web of Science ®Google Scholar
• Benedetti R, Conte M, Iside C, Altucci L. Epigenetic-based therapy: from single- to multi-target approaches. Int J Biochem Cell Biol. 2015;69:121–131. doi:10.1016/j.biocel.2015.10.016
   PubMed Web of Science ®Google Scholar
• Duan YT, Sangani CB, Liu W, Soni KV, Yao Y. New promises to cure cancer and other genetic diseases/disorders: epi-drugs through epigenetics. Curr Top Med Chem. 2019;19(12):972–994. doi:10.2174/1568026619666190603094439
   PubMed Web of Science ®Google Scholar
• Tomaselli D, Lucidi A, Rotili D, Mai A. Epigenetic polypharmacology: a new frontier for epi-drug discovery. Med Res Rev. 2020;40(1):190–244. doi:10.1002/med.21600
   PubMed Web of Science ®Google Scholar
• Bernardo MM, Kaplun A, Dzinic SH, et al. Maspin expression in prostate tumor cells averts stemness and stratifies drug sensitivity. Cancer Res. 2015;75(18):3970–3979. doi:10.1158/0008-5472.CAN-15-0234
   PubMed Web of Science ®Google Scholar
• Wawruszak A, Kalafut J, Okon E, et al. Histone deacetylase inhibitors and phenotypical transformation of cancer cells. Cancers (Basel). 2019;11(2):148. doi:10.3390/cancers11020148
   PubMed Web of Science ®Google Scholar
• Huang K, Liu Y, Gu C, Liu D, Zhao B. Trichostatin A augments esophageal squamous cell carcinoma cells migration by inducing acetylation of RelA at K310 leading epithelia-mesenchymal transition. Anticancer Drugs. 2020;31(6):567–574. doi:10.1097/CAD.0000000000000927
   PubMed Web of Science ®Google Scholar
• McClure JJ, Li X, Chou CJ. Advances and challenges of HDAC inhibitors in cancer therapeutics. Adv Cancer Res. 2018;138:183–211.
   PubMed Web of Science ®Google Scholar
• Tang DG. Understanding cancer stem cell heterogeneity and plasticity. Cell Res. 2012;22(3):457–472. doi:10.1038/cr.2012.13
   PubMed Web of Science ®Google Scholar
• Iliopoulos D, Hirsch HA, Wang G, Struhl K. Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc Natl Acad Sci U S A. 2011;108(4):1397–1402. doi:10.1073/pnas.1018898108
   PubMed Web of Science ®Google Scholar
• Konrad CV, Murali R, Varghese BA, Nair R. The role of cancer stem cells in tumor heterogeneity and resistance to therapy. Can J Physiol Pharmacol. 2017;95(1):1–15. doi:10.1139/cjpp-2016-0079
   PubMed Web of Science ®Google Scholar
• Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005;65(23):10946–10951. doi:10.1158/0008-5472.CAN-05-2018
   PubMed Web of Science ®Google Scholar
• Kong D, Banerjee S, Ahmad A, et al. Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells. PLoS One. 2010;5(8):e12445. doi:10.1371/journal.pone.0012445
   PubMed Web of Science ®Google Scholar
• Jaworska D, Krol W, Szliszka E. Prostate cancer stem cells: research advances. Int J Mol Sci. 2015;16(11):27433–27449. doi:10.3390/ijms161126036
   PubMed Web of Science ®Google Scholar
• Yun EJ, Zhou J, Lin CJ, et al. Targeting cancer stem cells in castration-resistant prostate cancer. Clin Cancer Res. 2016;22(3):670–679. doi:10.1158/1078-0432.CCR-15-0190
   PubMed Web of Science ®Google Scholar